← Back to Screener
MediWound Ltd. (MDWD)
Price$17.10
Favorite Metrics
Price vs S&P 500 (26W)-6.11%
Price vs S&P 500 (4W)-4.35%
Market Capitalization$222.17M
All Metrics
Book Value / Share (Quarterly)$3.40
P/TBV (Annual)5.43x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-13.82%
Cash Flow / Share (Quarterly)$-1.68
Price vs S&P 500 (YTD)-9.20%
Gross Margin (TTM)19.19%
Net Profit Margin (TTM)-140.80%
EPS (TTM)$-2.10
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-2.10
Revenue Growth (5Y)-4.86%
EPS (Annual)$-2.10
ROI (Annual)-45.56%
Gross Margin (Annual)19.19%
Net Profit Margin (5Y Avg)-91.44%
Cash / Share (Quarterly)$4.14
Revenue Growth QoQ (YoY)-68.03%
ROA (Last FY)-27.68%
Revenue Growth TTM (YoY)-16.14%
EBITD / Share (TTM)$-2.00
ROE (5Y Avg)-95.84%
Operating Margin (TTM)-148.98%
Cash Flow / Share (Annual)$-1.68
P/B Ratio5.09x
P/B Ratio (Quarterly)5.42x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)13.30x
Net Interest Coverage (TTM)-12.46x
ROA (TTM)-30.16%
EV / EBITDA (TTM)32.13x
EPS Incl Extra (Annual)$-2.10
Current Ratio (Annual)2.33x
Quick Ratio (Quarterly)2.17x
3-Month Avg Trading Volume0.10M
52-Week Price Return3.98%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.40
P/S Ratio (Annual)13.10x
Asset Turnover (Annual)0.20x
52-Week High$22.50
Operating Margin (5Y Avg)-81.10%
EPS Excl Extra (Annual)$-2.10
CapEx CAGR (5Y)43.02%
Tangible BV CAGR (5Y)24.22%
26-Week Price Return-2.13%
Quick Ratio (Annual)2.16x
13-Week Price Return0.12%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)2.33x
Enterprise Value$225.519
Revenue / Share Growth (5Y)-23.24%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)-2.71%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)4.04x
Pretax Margin (Annual)-139.81%
Cash / Share (Annual)$4.14
3-Month Return Std Dev44.01%
Gross Margin (5Y Avg)27.60%
Net Income / Employee (TTM)$-0
ROE (Last FY)-54.73%
Net Interest Coverage (Annual)-0.83x
EPS Basic Excl Extra (Annual)$-2.10
Receivables Turnover (TTM)5.28x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$-2.10
Receivables Turnover (Annual)5.28x
ROI (TTM)-54.24%
P/S Ratio (TTM)13.10x
Pretax Margin (5Y Avg)-90.90%
Revenue / Share (Annual)$1.49
Tangible BV / Share (Annual)$3.40
Price vs S&P 500 (52W)-25.85%
Year-to-Date Return-6.55%
5-Day Price Return-2.93%
EPS Normalized (Annual)$-2.10
ROA (5Y Avg)-37.35%
Net Profit Margin (Annual)-140.80%
Month-to-Date Return7.08%
Cash Flow / Share (TTM)$-1.35
EBITD / Share (Annual)$-2.16
Operating Margin (Annual)-148.98%
LT Debt / Equity (Annual)7.75x
ROI (5Y Avg)-79.59%
LT Debt / Equity (Quarterly)17.96x
EPS Basic Excl Extra (TTM)$-2.10
P/TBV (Quarterly)5.43x
P/B Ratio (Annual)5.42x
Inventory Turnover (TTM)4.04x
Pretax Margin (TTM)-139.81%
Book Value / Share (Annual)$3.40
Price vs S&P 500 (13W)-0.57%
Beta0.22x
P/FCF (Annual)29.62x
Revenue / Share (TTM)$1.32
ROE (TTM)-65.79%
52-Week Low$14.90
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceutical Preparations(15)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MDWDMediWound Ltd. | 13.10x | -16.14% | 19.19% | — | $17.10 |
CRONCronos Group Inc. Common Share | 7.06x | 24.63% | 42.81% | -49.98% | $2.68 |
TLRYTilray Brands, Inc. Common Stock | 0.92x | 3.82% | 27.68% | — | $6.79 |
CGCCanopy Growth Corporation Common Shares | 2.42x | 0.59% | 26.56% | — | $1.15 |
NAGENiagen Bioscience, Inc. Common Stock | 2.93x | 29.95% | 64.28% | — | $4.73 |
USNAUSANA Health Sciences Inc | 0.38x | 5.88% | 78.29% | -37.04% | $19.06 |
SNDLSundial Growers Inc. Common Shares | 0.58x | 2.82% | 27.33% | — | $1.51 |
ACBAurora Cannabis Inc. Common Shares | 0.78x | 16.54% | 1.35% | — | $3.61 |
FTLFFitLife Brands, Inc. Common Stock | 1.34x | 1.34% | 37.58% | -20.04% | $9.25 |
BTMDBiote Corp. Class A Common Stock | 0.41x | -2.52% | 71.46% | -26.84% | $2.10 |
NAIINatural Alternatives International Inc. | 0.12x | 10.92% | 9.06% | — | $2.69 |
About
MediWound Ltd is a biopharmaceutical company developing treatments for severe burns and hard-to-heal wounds. Its lead product, NexoBrid, is FDA-approved for eschar removal in severe burns and offers a non-surgical alternative to conventional debridement. The company is advancing a pipeline including EscharEx for chronic wound debridement and MW005 for non-melanoma skin cancer, with revenue primarily generated in the United States.